Physician profile
Lawrence A Schaeffer
NPI 1528017324
$5,762.82
in general payments reported to CMS, 2019-2025
17 companies · $31.85 in 2025
The $31.85 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,674 · 2020: $382 · 2021: $289 · 2022: $226 · 2023: $147 · 2024: $14.28 · 2025: $31.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $192.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,874.82 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $452.40 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $284.26 | 2019-2023 | |
| Genzyme Corporation | $272.34 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $189.04 | 2021-2022 | |
| Emd Serono, INC. | $150.54 | 2019 | |
| Kyowa Kirin, INC. | $144.22 | 2020 | |
| Horizon Therapeutics Plc | $118.84 | 2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $116.18 | 2019 | |
| Celgene Corporation | $31.62 | 2021-2024 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $29.05 | 2023-2025 | Nuedexta |
| Acorda Therapeutics, INC | $22.65 | 2019 | |
| Tanabe Pharma America, INC. | $18.83 | 2019 | |
| Abbott Laboratories | $17.53 | 2022 | |
| Argenx US, INC. | $16.24 | 2025 | Vyvgart Hytrulo, Vyvgart |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $12.73 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Schaeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.